Search hospitals > New Mexico > Albuquerque
University of New Mexico Cancer Center
Claim this profileAlbuquerque, New Mexico 87102
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
695 reported clinical trials
28 medical researchers
Summary
University of New Mexico Cancer Center is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Parotid Gland Cancer, Cancer, Breast Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse and other specialties. University of New Mexico Cancer Center is involved with conducting 695 clinical trials across 675 conditions. There are 28 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Jessica M. Valdez.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Atul KumarUniversity of New Mexico Cancer Center5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
38 drugs studied
Carolyn Y. MullerUniversity of New Mexico Cancer Center1 year of reported clinical research
Studies Endometrial Cancer
Studies Parotid Gland Cancer
23 reported clinical trials
44 drugs studied
Ursa A. Brown-GlabermanUniversity of New Mexico Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Parotid Gland Cancer
20 reported clinical trials
45 drugs studied
Jessica M. ValdezUniversity of New Mexico Cancer Center5 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
20 reported clinical trials
57 drugs studied
Clinical Trials running at University of New Mexico Cancer Center
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Parotid Gland Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Skin Cancer
Breast cancer
Squamous Cell Carcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of New Mexico Cancer Center?
Where is University of New Mexico Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of New Mexico Cancer Center accept?
What awards or recognition has University of New Mexico Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.